# Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

> **NCT03756064** · NA · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer
- Neoplasm, Breast
- Breast Diseases

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab
- **DRUG:** Docetaxel
- **DRUG:** Carboplatin
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03756064
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2020-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03756064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03756064, "Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03756064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*